J&J Settles Texas Lawsuit (JNJ)
The Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE: JNJ) has reached an agreement with the state of Texas to pay $158 million to settle all claims related to overcharging the state’s Medicaid program for the anti-psychotic drug Risperdal from…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE: JNJ) has reached an agreement with the state of Texas to pay $158 million to settle all claims related to overcharging the state’s Medicaid program for the anti-psychotic drug Risperdal from 1994-2008. MarketWatch reports that the original plaintiff, his attorneys, the state of Texas, and the federal government will share the settlement amount.
Contact [email protected] for any questions or corrections.







